Interaction Between Sex and Organic Anion‐Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib‐N‐Oxide and Regorafenib‐Glucuronide in Mice

Regorafenib: A Review in Metastatic Colorectal Cancer

(2018) Sohita Dhillon   DRUGS

Regorafenib: A Review in Hepatocellular Carcinoma

(2018) Young-A. Heo et al.   DRUGS

Development and validation of an analytical method for regorafenib and its metabolites in mouse plasma

(2018) Qiang Fu et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity

(2018) Alix F. Leblanc et al.   JOURNAL OF CLINICAL INVESTIGATION

Metabolic profiling of the anti-tumor drug regorafenib in mice

(2018) Yi-Kun Wang et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Growing Role of Regorafenib in the Treatment of Patients with Sarcoma

(2018) Mark Agulnik et al.   Targeted Oncology

Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice

(2016) Andrea N. Edginton et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models

(2016) Dieter Zopf et al.   Cancer Medicine

Regorafenib Is Transported by the Organic Anion Transporter 1B1 and the Multidrug Resistance Protein 2

(2015) Hiroki Ohya et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b

(2015) A. Vasilyeva et al.   CANCER RESEARCH

Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib

(2015) Camille Tlemsani et al.   Expert Opinion on Drug Metabolism & Toxicology

ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development

(2014) Young Choi et al.   CURRENT PHARMACEUTICAL DESIGN

Population Pharmacokinetic Modeling of the Unbound Levofloxacin Concentrations in Rat Plasma and Prostate Tissue Measured by Microdialysis

(2013) Felipe K. Hurtado et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide

(2013) E. I. Zimmerman et al.   CLINICAL CANCER RESEARCH

Importance of Peptide Transporter 2 on the Cerebrospinal Fluid Efflux Kinetics of Glycylsarcosine Characterized by Nonlinear Mixed Effects Modeling

(2013) Yeamin Huh et al.   PHARMACEUTICAL RESEARCH

OATP1B1 Polymorphism as a Determinant of Erythromycin Disposition

(2012) C S Lancaster et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver

(2012) Evita van de Steeg et al.   JOURNAL OF CLINICAL INVESTIGATION

Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis

(2011) R.A. Hilger et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Functions of OATP1A and 1B transporters in vivo: insights from mouse models

(2011) Dilek Iusuf et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Physiologically Based Pharmacokinetic/Pharmacodynamic Animal-to-Man Prediction of Therapeutic Dose in a Model of Epilepsy

(2010) Anne Brochot et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

The Role of Organic Anion–Transporting Polypeptides and Their Common Genetic Variants in Mycophenolic Acid Pharmacokinetics

(2009) N Picard et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS